For the treatment of DMD patients with confirmed exon skipping, Viltolarsen and Golodirsen, have been approved by U.S. FDA for marketing for DMD patients with confirmed dystrophin gene amenable to exon 53 skipping, eteplirsen for exon 52 skipping, casimersen for exon 45 skipping. Here, DMD is linked to Duchenne muscular dystrophy.